Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol

Sitbon, O.; McLaughlin, V. V.; Badesch, D. B.; Barst, R. J.; Black, C.; Galiè, N.; Humbert, M.; Rainisio, M.; Rubin, L. J.; Simonneau, G.
December 2005
Thorax;Dec2005, Vol. 60 Issue 12, p1025
Academic Journal
Background: The oral dual endothelin receptor antagonist bosentan improves exercise capacity and delays clinical worsening in patients with pulmonary arterial hypertension, but its use could delay starting intravenous epoprostenol, a life saving treatment. Methods: Survival in patients with functional class III idiopathic pulmonary arterial hypertension (PAH) treated with bosentan in clinical trials was compared with historical data from similar patients treated with epoprostenol in the clinic. Statistical methods were used to adjust for possible underlying differences between the two groups. Results: Baseline Factors for the 139 patients treated with bosentan and the 346 treated with epoprostenol suggested that the epoprostenol cohort had more severe disease-that is, a lower cardiac index (2.01 v 2.39 I/min/m²) and higher pressures and resistance. Kaplan-Meier survival estimates after 1 and 2 years were 97% and 91%, respectively, in the bosentan cohort and 91 % and 84% in the epoprostenol cohort. Cox regression analyses adjusting for differences in baseline factors showed a greater probability of death in the epoprostenol cohort (hazard ratio 2.2 (95% confidence interval 1.2 to 4.0) in the model adjusted for haemodynamics). Alternative regression analyses and analyses to adjust for different data collection dates gave consistently similar results. When matched cohorts of 83 patients each were selected, survival estimates were similar. In the bosentan cohort 87% and 75% of patients followed for 1 and 2 years, respectively, remained on monotherapy. Conclusions: No evidence was found to suggest that initial treatment with oral bosentan, followed by or with the addition of other treatment if needed, adversely affected the long term outcome compared with initial intravenous epoprostenol in patients with class III idiopathic PAH.


Related Articles

  • Sildenafil is useful in pulmonary arterial hypertension. Karadi, R. L. // Thorax;Feb2006, Vol. 61 Issue 2, p176 

    The abstract of the study "Sildenafil is useful in pulmonary arterial hypertension," by N. Galie, H.A. Ghofrani, A. Tarbicki and colleagues, is presented. The multicenter, double blind, placebo controlled study was performed in 278 patients with pulmonary arterial hypertension. The patients were...

  • Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST): study protocol for a pilot randomised controlled trial. Shaw, Lisa; Price, Christopher; McLure, Sally; Howel, Denise; McColl, Elaine; Ford, Gary A // Trials;2011, Vol. 12 Issue 1, p152 

    Background: High blood pressure during acute stroke is associated with poorer stroke outcome. Previous trials have failed to show benefit from lowering blood pressure but treatment may have been commenced too late to be effective. The earliest that acute stroke treatments could be...

  • Inhalation of nebulized nitroglycerin, a nitric oxide donor, for the treatment of pulmonary hypertension induced by high pulmonary blood flow. Kan Puikuan; Zhang Chunyu; Fan Jin; Tang Chaoshu; Du Junbao // Heart & Vessels;May2006, Vol. 21 Issue 3, p169 

    This study explores the effect and mechanisms of inhalation of nebulized nitroglycerin (Neb-NTG) on pulmonary hypertension induced by high pulmonary blood flow. An aortocaval shunt was produced in rats. Twelve weeks after the operation, rats started to inhale Neb-NTG. After 15 weeks, pulmonary...

  • Impact of Pulmonary Hypertension on Tricuspid Valve Function. Casa, Lauren; Dolensky, Joseph; Spinner, Erin; Veledar, Emir; Lerakis, Stamatios; Yoganathan, Ajit // Annals of Biomedical Engineering;Apr2013, Vol. 41 Issue 4, p709 

    Pulmonary arterial hypertension (PAH) results in increased right ventricle (RV) afterload leading to RV remodeling, tricuspid regurgitation (TR), and RV failure. Though characterizing the mechanisms of TR in PAH may suggest new treatment strategies, the mechanisms leading to TR in PAH have not...

  • Oral therapy with the endothelin antagonist bosentan improves the clinical, exercise and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.  // Cardiology in the Young;May2005 Supplement 2, Vol. 15 Issue S2, p32 

    This article cites a prospective nonrandomised open clinical study, which attempted to evaluate the clinical, exercise and haemodynamic effect of chronic oral administration of the nonselective endothelin receptor antagonist bosentan on patients with pulmonary arterial hypertension related to...

  • When is it too EARLY to start bosentan in pulmonary arterial hypertension? Magdy, F. // Thorax;Oct2008, Vol. 63 Issue 10, p865 

    The article reports the therapeutic use of bosentan (dual endothelin receptor antagonist) in pulmonary arterial hypertension, which is presented under the EARLY trial study. It defines pulmonary arterial hypertension as a debilitating progressive disease that leads to right heart failure and...

  • Combination drug therapies may improve efficacy, reduce side effects in PAH.  // Formulary;Jan2006, Vol. 41 Issue 1, p46 

    The article focuses on the role of combination drug therapies in improving efficacy and reducing side effects in pulmonary arterial hypertension. A randomized, double-blind, clinical study explored the combination of inhaled iloprost and bosentan. Improvements in post-inhalation hemodynamics...

  • Effect of hypertension on foveolar choroidal haemodynamics. Niknam, R. M.; Schocket, L. S.; Metelitsina, T.; DuPont, J. C.; Grunwald, J. E. // British Journal of Ophthalmology;Oct2004, Vol. 88 Issue 10, p1263 

    Aims: To assess the effect of systemic hypertension on the choroidal circulation in subjects with a normal eye examination. Methods: Laser Doppler flowmetry was used to determine relative choroidal blood velocity (Chvel), volume (Chvol), and flow (Chflow) in the centre of the fovea. Measurements...

  • Electrocardiographic and Hemodynamic Correlations in Primary Pulmonary Hypertension. Kanemoto, Nariaki // Angiology;Sep1988, Vol. 39 Issue 9, p781 

    In order to evaluate the pulmonary hemodynamics in primary pulmonary hypertension, the relation between the standard 12-lead electrocardiogram (ECG) and pulmonary hemodynamics as determined by right-heart catheterization was analyzed. Significant positive correlations were noted between...


Read the Article


Sign out of this library

Other Topics